The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Characterization of lymphoid infiltrates in prostatectomy specimens post neoadjuvant hormonal therapy using quantitative immunofluorescence and RNA FISH.

Print

Sub-category:
Prostate Cancer

Category:
Genitourinary Cancer

Meeting:
2009 ASCO Annual Meeting

Session Type and Session Title:
This abstract will not be presented at the 2009 ASCO Annual Meeting but has been published in conjunction with the meeting.

Abstract No:
e16104

Citation:
J Clin Oncol 27, 2009 (suppl; abstr e16104)

Author(s):
M. J. Donovan, F. Khan, D. Powell, P. Capodieci, M. Gleave, I. Taylor, J. Gomez-Navarro, C. Cordon-Cardo; Aureon Biosciences, Yonkers, NY; Prostate Center at Vancouver General Hospital, Vancouver, BC, Canada; Pfizer, New London, CT; Columbia University, New York, NY

Abstract:

Background: Immunotherapy for advanced prostate cancer requires an understanding of the host response including lymphocyte subsets and cytokine expression. Using quantitative immunofluorescence (IF), image analysis and RNA FISH we examined a series of prostatectomy specimens from patients, ± neoadvjuvant hormonal therapy (NHT) and determined their baseline immune characteristics. Methods: CD4,8,25,45,68,69,86 and Foxp3 were evaluated by IF and IFNg with RNA FISH on prostatectomy specimens from 40 patients with T1c-T3 prostate cancer; 20 control and 20 post long-term NHT. Sections were analyzed with three multiplex IF assays, triplicate images acquired with spectral imaging, digitally masked and processed with IF image analysis software. IFNg RNA transcript localization was performed on all 40 patients using published protocols. Results: There was a predominance of CD8 in both control and NHT patients with a high but variable level of CD86 and 69 across the entire cohort, reflecting T cell activation. CD68 appeared reduced in NHT, but this change was not statistically significant. Number of Treg (CD4+/CD25+/Foxp3+) cells were similar between groups; however, in NHT an increased Treg population was associated with an elevated preoperative PSA compared with controls (p<0.05). IFNg transcript activity was low in the entire cohort and limited to tumor epithelial cells. Conclusions: The prominent CD8 expression and low level of IFNg in both control and NHT groups suggest an ongoing but not overly active immune response. Multiplex IF and in situ RNA FISH are useful tools for developing a disease phenotype and provide the necessary parameters for evaluating gene-protein expression especially in pharmacodynamic studies.


Abstract Disclosures

Faculty and Discussant Disclosures

Annual Meeting Planning Committee Disclosures

2009 Annual Meeting Proceedings Part I Errata

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


  Associated Presentation(s):

    

No items found.


  Other Abstracts in this Sub-Category:

    

1. Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk men.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 5000   First Author: V. N. Giri
Category: Genitourinary Cancer - Prostate Cancer

    

2. Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials Consortium Trial.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 5001   First Author: G. Netto
Category: Genitourinary Cancer - Prostate Cancer

    

3. Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 5002   First Author: N. Mitsiades
Category: Genitourinary Cancer - Prostate Cancer

    

More...


  Abstracts by M. J. Donovan:

    

1. Use of a pretreatment systems pathology model to predict the likelihood of disease progression in patients treated with primary radiotherapy.

Meeting: 2010 ASCO Annual Meeting   Abstract No: 4651   First Author: M. J. Donovan
Category: Genitourinary Cancer - Prostate Cancer

    

2. Use of a preoperative systems pathology model to predict the likelihood of favorable pathology (FP) at prostatectomy and subsequent outcomes.

Meeting: 2010 Genitourinary Cancers Symposium   Abstract No: 179   First Author: M. J. Donovan
Category: Prostate Cancer: Early/Localized disease, Locally Advanced/Recurrent/Advanced disease, and Biology

    

3. Characterization of lymphoid infiltrates in prostatectomy specimens post neoadjuvant hormonal therapy using quantitative immunofluorescence and RNA FISH.

Meeting: 2009 ASCO Annual Meeting   Abstract No: e16104   First Author: M. J. Donovan
Category: Genitourinary Cancer - Prostate Cancer

    

More...


  Presentations by M. J. Donovan:

    

1. Use of a pretreatment systems pathology model to predict the likelihood of disease progression in patients treated with primary radiotherapy.

Meeting: 2010 ASCO Annual Meeting
Presenter: Michael J. Donovan
Session: Genitourinary Cancer (General Poster Session)

    

2. A preoperative systems pathology model predicts the likelihood of favorable pathology (FP) at prostatectomy and subsequent outcomes

Meeting: 2010 Genitourinary Cancers Symposium
Presenter: Michael J. Donovan, MD, PhD
Session: General Poster Session C: Prostate Cancer (General Poster Session)

    

3. Characterization of lymphoid infiltrates in prostatectomy specimens post neoadjuvant hormonal therapy using quantitative immunofluorescence and RNA FISH.

Meeting: 2009 Genitourinary Cancers Symposium
Presenter: Michael J Donovan, MD, PhD
Session: General Poster Session A: Prostate Cancer (Poster Presentation)

    

More...


  Educational Book Manuscripts by M. J. Donovan:

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.